Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00734305 · ClinicalTrials.gov registry record · Phase 1

Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

A Phase 1 study of Advanced Solid Tumors, sponsored by Merrimack Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
44
Enrollment target
3
Study locations

NCT00734305 is a Phase 1 study of Advanced Solid Tumors that has completed, run by Merrimack Pharmaceuticals. The registered enrollment target is 44 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (78% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00734305, a Phase 1 study of Advanced Solid Tumors, has completed, sponsored by Merrimack Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
44 participants
Enrollment target
3
Study locations

Study Summary

This study was a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design to determine maximum tolerated dose/recommended Phase 2 dose.

Conditions Studied

Advanced Solid Tumors

Interventions

  • DRUG MM-121

Study Locations (3)

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Pennsylvania

  • Fox Chase Cancer Center - Philadelphia

Tennessee

  • The Vanderbilt-Ingram Cancer Center - Nashville

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2008-07
Est. Completion 2013-09
Phase Phase 1

Sponsor

Merrimack Pharmaceuticals

22 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00734305

The ClinicalTrials.gov registry entry for NCT00734305 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (78% lower). The listed sponsor is Merrimack Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which MM-121 is the first listed.

NCT00734305 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, Pennsylvania, Tennessee.

Frequently Asked Questions

What is clinical trial NCT00734305 about?

NCT00734305 is a clinical study titled "Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment". This study was a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design to determine maximum tolerated dose/recommended Phase 2 dose.

What is the current status of trial NCT00734305?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2008-07. Estimated completion is 2013-09.

What conditions does trial NCT00734305 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT00734305?

The interventions under investigation include: MM-121 (DRUG).

Who is sponsoring clinical trial NCT00734305?

This trial is sponsored by Merrimack Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00734305 being conducted?

This trial has 3 study locations across Massachusetts, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.